Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 9/30/15 → 8/30/17 |
Financiación
- Nivalis Therapeutics Incorporated: 44.539,00 US$
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis who are Homozygous for the F508del-CFTR Mutation and Being Treated with lumacaftor/ivacaftor (ORKAMBI)
- Anstead, Michael (PI)
- Danov, Zoran (CoI)
- Kanga, Jamshed (CoI)
- Tupayachi Ortiz, Maria (CoI)